drugset / Trial / NCT03935204
Immunogenicity Study of Recombinant Human Papillomavirus Vaccine(6,11,16,18,31,33,45,52,58 Type)(E.Coli)
Phase 2
Completed
627 enrolled
Xiamen University
Beijing Wantai Biological Pharmacy Enterprise Co., Ltd. · collabXiamen Innovax Biotech Co., Ltd · collab
RandomizedParallel-groupDouble-blindPrevention
Summary
This phase II clinical study was designed to evaluate the immunogenicity and safety of Recombinant Human Papillomavirus Vaccine (6,11,16,18,31,33,45,52,58 Type)(E.Coli)(hereafter called HPV vaccine), manufactured by Xiamen Innovax Biotech CO., LTD., in healthy adults aged 18-45 years old.
Timeline
- Start
- 2019-05-13
- Primary completion
- 2019-10-18
- Completion
- 2021-04-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Recombinant Human Papillomavirus Vaccine (6,11,16,18,31,33,45,52,58 Type)(E.Coli) | Vaccine | 270 ug | Intramuscular |
| Subject | Recombinant Human Papillomavirus Vaccine (6,11,16,18,31,33,45,52,58 Type)(E.Coli) | Vaccine | 1 ml | Intramuscular |